Abstract
Natural killer (NK) cells (CD56(+)CD3(-)) are large, granular immunocytes that play a very pivotal role in the anti-inflammatory response and tumor surveillance. As an ideal cytotoxic lymphocyte (CTL), NK cells have attracted much attention in clinical trials. However, an insufficient number and their limited life span are bottlenecks that limit the application of NK cells in adoptive immunotherapy. Interleukins such as IL-2, IL-15 and IL-18 are recognized as factors that stimulate NK cells and have been used in NK cells ex vivo expansion. Similar to IL-2 and IL-15, IL-21 is a common γ-chain cytokine that is important in NK cell activation, maturation and proliferation. The present study aims to assess the effects of membrane-bound and soluble IL-21 on primary human NK cells during ex vivo expansion. IL-21 was found to have multiple effects on NK cells, increasing their cytotoxicity in a concentration-dependent manner by up-regulating IFN-γ and Granzyme-B expression. Nevertheless, at a high concentration (50 ng/mL), IL-21 curtailed the life span of NK cells by significantly inducing apoptosis. Moreover, when treated with IL-21, the number of NKT (CD56(+)CD3(+)) cells increased among peripheral blood mononuclear cells (PBMCs) du...Continue Reading
References
Nov 8, 2001·Trends in Immunology·M A CooperM A Caligiuri
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Apr 24, 2002·Immunity·Marion T KasaianMichael J Grusby
Dec 6, 2003·The Journal of Allergy and Clinical Immunology·Tania HabibKenneth Kaushansky
Jan 6, 2005·Blood·Jeffrey S MillerPhilip B McGlave
Mar 10, 2005·Blood·Chihaya ImaiDario Campana
Jul 20, 2007·Immunology·Katy WendtRoland Jacobs
Nov 17, 2007·Immunology·Kresten SkakDorthe Lundsgaard
Jan 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey E RubnitzWing Leung
Jun 15, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Duck ChoDario Campana
Jul 20, 2010·Immunotherapy·Lisbeth BarkholtM Sirac Dilber
Aug 13, 2010·Cancer Immunology, Immunotherapy : CII·Eleni G IliopoulouSonia A Perez
Sep 21, 2010·Cytotherapy·Melissa A GellerJeffrey S Miller
Jan 18, 2011·Cancer Immunology, Immunotherapy : CII·Emilie P BuddinghArjan C Lankester
Jan 27, 2012·PloS One·Cecele J DenmanDean A Lee
May 9, 2012·PloS One·Yuezhou ChenLili Huang
Dec 5, 2012·The Journal of International Medical Research·H DongH Xi
Jul 31, 2013·Oncoimmunology·Saskia Jam SantegoetsTanja D de Gruijl
Aug 8, 2013·Astrobiology·Qi LiQingsheng Huang
May 27, 2014·Cellular Immunology·Bo JiangWeiqun Yan
Jun 22, 2014·Cytotherapy·Dong-Pyo LimDuck Cho
Citations
Oct 29, 2015·Journal of Immunotoxicology·Ghasem GhalamfarsaFarhad Jadidi-Niaragh
Oct 16, 2015·Immunobiology·Tohid GharibiZohreh Babaloo
May 11, 2016·Proceedings of the National Academy of Sciences of the United States of America·Catharina C GrossHeinz Wiendl
Oct 21, 2016·Oncoimmunology·Markus GranzinAdelheid Cerwenka
Dec 6, 2018·PloS One·Maria A StreltsovaElena I Kovalenko
Jun 19, 2018·Transplantation·Duilio PaganoSalvatore Gruttadauria
Apr 19, 2019·Human Gene Therapy Methods·Olaf OberschmidtStephan Kloess
Aug 25, 2017·Blood·Stefan O CiureaRichard E Champlin
May 12, 2017·Frontiers in Immunology·Markus GranzinEvelyn Ullrich
Mar 21, 2020·Cancers·Aline Pfefferle, Nicholas D Huntington
Feb 23, 2017·Annals of Dermatology·Doaa Salah HegabMohamed Attia
Jul 1, 2017·Frontiers in Immunology·Juliane WagnerEvelyn Ullrich
Jan 24, 2019·International Journal of Molecular Sciences·Maria A StreltsovaElena I Kovalenko
Jan 25, 2018·Immunology and Cell Biology·Sofya A ErokhinaElena I Kovalenko
Jan 8, 2021·Journal of Hematology & Oncology·Sizhe LiuJennifer Wu
Feb 7, 2021·Cancers·Valérie Janelle, Jean-Sébastien Delisle